Last week, the small end of town was where all the action was in biotech-land with Biotron (ASX:BIT) up 97%, newcomer Innate Therapeutics (ASX:IIL) up 33% and...

Last week, the small end of town was where all the action was in biotech-land with Biotron (ASX:BIT) up 97%, newcomer Innate Therapeutics (ASX:IIL) up 33% and Anteo Diagnostics (ASX:ADO) up 27%. BIT sky-rocketed after announcing interim data from a Phase-2 trial showing its drug eliminated the hepatitis-C virus in patients infected with both hepatitis-C and HIV. BIT's price touched $0.31, a 300% gain on the previous day, and closed the week at $0.17. The price gains in ADO and IIL occurred despite the company's not making any announcements. Elsewhere, Alchemia (ASX:ACL) brought in some very early stage cancer drugs while the market awaits data from its Phase-3 trial and Phosphogenics (ASX:POH) set the refresh button on its Board with only one of the original directors remaining. Calzada (ASX:CZD) got FDA clearance for its wound dressing. The Canaccord Biotech Index closed flat and $113M of shares changed hands.